Telescope Innovations Delivers Continued Strong Sales Revenue Growth in First Fiscal Quarter 2026
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE:J4U) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended November 30, 2025 (Q1). The Company generated revenues of $2.7 million during this period, driven by continued market adoption of its flagship product, DirectI
Technology, Chemical, Pharmaceuticals, Psychedelics
2026-01-30 7:28 PM EST | Telescope Innovations Corp.
Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CB
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-27 10:00 AM EST | Neural Therapeutics Inc.
Telescope Innovations Expands Lithium Development Infrastructure and Achieves Key Material Validation Milestones
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") is a leader in Physical AI, Self-Driving Laboratories, and other enabling technology to support autonomous laboratory infrastructure. The Company is pleased to provide an update on the progress of its lithium processing portfolio. Our focus remains on securing a sustainable, on-shore supply of critical battery materials t
Technology, Chemical, Pharmaceuticals, Psychedelics
2026-01-27 8:00 AM EST | Telescope Innovations Corp.
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 n
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-26 7:00 AM EST | Optimi Health Corp.
Telescope Innovations Plans Expansion of DirectInject-LC(TM) Technology Ecosystem to Fuel the Physical AI Revolution
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - Telescope Innovations Corp., (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), is a leader in Physical AI, Self-Driving Laboratories, and enabling technology supporting autonomous laboratory infrastructure. The Company is pleased to provide a look at its planned 2026 technology development pipeline, which aligns with its Self-Driving Lab (SDL) architecture for autonomous chemistry R&D. Buildin
Technology, Chemical, Pharmaceuticals, Psychedelics
2026-01-20 8:00 AM EST | Telescope Innovations Corp.
Entheon Announces Execution of Business Combination Agreement with Nutravisor
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a definitive business combination agreement (the "Business Combination Agreement") with Nutravisor Inc. ("Nutravisor"), dated January 19, 2026, pursuant to which the parties have agreed to complete a business combination involving a "three-cornered" amalgamation of
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-01-19 5:28 PM EST | Entheon Biomedical Corp.
Optimi Health Announces Equity Incentive Grants and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness. Equity Incentive Grants Optimi announces that, pursuant to its equity incentive plan and subject
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-16 7:00 AM EST | Optimi Health Corp.
Psyched Wellness Sells Out of First Run of Calmer and Announces New Production Run
Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched" or the "Company"), a life sciences company dedicated to developing and commercializing products derived from the Amanita Muscaria mushroom, is pleased to announce a key commercial milestone for its newest product, Calmer. The Company has officially sold out of its initial production run following strong early demand and positive consumer feedback.
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-01-15 12:42 PM EST | Psyched Wellness Ltd.
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic treatments for mental health therapies, today announced that management has been invited to present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026. Chief Executive Officer Dane Stevens is scheduled to host virtual one-on-one meetings with institutional invest
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-14 7:30 AM EST | Optimi Health Corp.
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - January 5, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has closed the previously announced (see press release dated October 31, 2025) acquisition (the "Transaction") of limited partnership units of Canurta Limited Partnership ("Canurta"), the p
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2026-01-05 8:00 AM EST | PharmaDrug Inc.
Telescope Innovations Outlines Global Market Opportunity for Self-Driving Labs and the Rising Adoption of Physical AI
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, is pleased to provide a strategic update regarding the accelerating commercial adoption of Self-Driving Labs (SDLs) and the global expansion of Physical AI. This update follows the Company's recent successful deployment of a
Technology, Chemical, Pharmaceuticals, Psychedelics
2026-01-05 8:00 AM EST | Telescope Innovations Corp.
Telescope Grants Stock Options, RSUs and Settles Debt with Shares
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (the "Company"), a leading developer of advanced technologies and services for the global pharmaceutical and high-value chemical industries announces that it has authorized the grant of incentive stock options (the "Options"), restricted share units (the "RSUs") as well as the issuance of common shares to settle outstanding fees owed to its
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-31 8:00 AM EST | Telescope Innovations Corp.
Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, reports financial results for the fiscal year ended August 31, 2025. The Company generated revenues of $5.8 million during this period, with an Adjusted EBITDA loss of $402K (Figure 1). Telescope continues
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-23 8:00 PM EST | Telescope Innovations Corp.
Entheon Announces Letter of Intent with Nutravisor Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a binding Letter of Intent (the "LOI") dated December 18, 2025, with Nutravisor Inc. ("Nutravisor") whereby Entheon will acquire all of the issued and outstanding common shares of Nutravisor (the "Proposed Transaction"). Upon completion of the Proposed T
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2025-12-22 9:30 AM EST | Entheon Biomedical Corp.
Steep Hill Provides Update on Transaction with Good Purpose Investments
Toronto, Ontario--(Newsfile Corp. - December 19, 2025) - Steep Hill Inc. (CSE: STPH) ("Steep Hill" or the "Company") is pleased to provide an update on its ongoing transaction with Good Purpose Investments Inc. ("Good Purpose"). Good Purpose is a privately held British Columbia corporation that operates a business engaged in the manufacturing, marketing, and distribution of textiles made from recycled plastics under the trade name "Waste2Wear." Through its subs
Retail, Cannabis, Psychedelics, Cannabis Manufacturer
2025-12-19 5:30 PM EST | Steep Hill Inc.
Optimi Health Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, is pleased to announce the appointment of Mr. Jason Mosberian as a director of the Company, effective immediately (the "Appointment"). Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-18 7:00 AM EST | Optimi Health Corp.
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce that, further to its news release o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-10 8:00 PM EST | Quantum BioPharma Ltd.
Telescope Innovations Installs Korea's First Self-Driving Lab for Pharma R&D and Education
HIGHLIGHTS Telescope Innovations' installation of Korea's first Self-Driving Lab for pharmaceutical research completed just three weeks after contract signing Project facilitated by collaboration with the Acceleration Consortium (AC) and supported on site by two-time Chemistry Nobel Laureate Prof. Barry Sharpless Successful SDL delivery demonstrates Telescope's growing commercial momentum, positioning Telescope and the AC to expand SDL adoption across phar
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-09 8:00 AM EST | Telescope Innovations Corp.
Numinus Wellness Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update. Change of auditors On October 10, 2025, the Company announced that Davidson & Company LLP ("Davidson") had resigned as the Company's i
2025-12-01 5:00 PM EST | Numinus Wellness Inc.
Red Light Holland Reports Second Quarter 2026 Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 1, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms, mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal recreational market within the Netherlands, in compliance with all applicable laws, announces its financial and operat
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-12-01 4:30 PM EST | Red Light Holland Corp.